SFS
CYCN icon

Sowell Financial Services’s Cyclerion Therapeutics CYCN Stock Holding History

Sowell Financial Services’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-18
Closed -$4K – 2532
2019
Q3 		$4K Buy
+18
New +$3.89K ﹤0.01% 1822

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sowell Financial Services's CYCN Position: Q4 2019 in Review

Sowell Financial Services sold out of Cyclerion Therapeutics (CYCN) in Q4 2019, closing a stake of 18 shares — an estimated $4K sold.

Sowell Financial Services first reported a position in CYCN in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 77 funds tracked by Wall St. Rank hold CYCN as of Q4 2019.

  • Sowell Financial Services reported no remaining Cyclerion Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sowell Financial Services sold 18 Cyclerion Therapeutics shares in Q4 2019, an estimated $4K.
  • Sowell Financial Services first reported a position in Cyclerion Therapeutics in Q3 2019 and held it in 1 quarter.
  • Sowell Financial Services's Cyclerion Therapeutics position peaked at $4K in Q3 2019.
  • 77 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2019.

Based on Sowell Financial Services's 13F filing for Q4 2019, filed 7 Feb 2020.